Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry

Portopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear. We performed a retrospective cohort study of PoPH patients from the international pulmonary hypertension (PH) meta-registry, PVRI GoDeep. PAH was defined by a mean pulmonary arterial pressure > 20 mmHg, pulmonary arterial wedge pressure

  • Jose, A.
  • Yogeswaran, A.
  • Fuenderich, M.
  • Kiely, D.
  • Sweatt, A. J.
  • Zamanian, R. T.
  • Hassoun, P. M.
  • Mouawad, A.
  • Balasubramanian, A.
  • Wilkins, M.
  • Lawrie, A.
  • Howard, L.
  • Sahay, S.
  • Olschewski, H.
  • Kovacs, G.
  • Saleh, K.
  • Sabbour, H.
  • Eichstaedt, C. A.
  • Grünig, E.
  • Giannakoulas, G.
  • Arvanitaki, A.
  • Sirenko, Y.
  • Torbas, O.
  • Cajigas, H.
  • Frantz, R.
  • Scelsi, L.
  • Ghio, S.
  • Majeed, R. W.
  • Wilhelm, J.
  • Ghofrani, H. A.
  • Grimminger, F.
  • Tello, K.
  • Elwing, J.
  • Seeger, W.
Publication details
DOI: 10.1002/pul2.70121
Journal: Pulm Circ
Pages: e70121
Number: 3
Work Type: Original
Access number: 40636151
More information
chevron-down